Literature DB >> 28339729

How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?

Anne Musters1, Sander W Tas1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 28339729     DOI: 10.1093/rheumatology/kex016

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  2 in total

1.  Mixed connective tissue disease: state of the art on clinical practice guidelines.

Authors:  Benjamin Chaigne; Carlo Alberto Scirè; Rosaria Talarico; Tobias Alexander; Zahir Amoura; Tadej Avcin; Lorenzo Beretta; Andrea Doria; Aurelien Guffroy; Vera Guimarães; Éric Hachulla; Thomas Krieg; David Launay; Gemma Lepri; Pia Moinzadeh; Ulf Müller-Ladner; Simona Rednic; Ana Rodrigues; Sander W Tas; Ronald F van Vollenhoven; Ana Vieira; Stefano Bombardieri; João Eurico Fonseca; Ilaria Galetti; Matthias Schneider; Vanessa Smith; Maurizio Cutolo; Marta Mosca; Rebecca Fischer-Betz
Journal:  RMD Open       Date:  2018-10-18

Review 2.  Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic.

Authors:  S W Tas; G J Wolbink; L Boekel; F Hooijberg; E H Vogelzang; P L Klarenbeek; W H Bos
Journal:  Arthritis Res Ther       Date:  2021-08-05       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.